XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Crosses Below 200-Day Moving Average – What’s Next?

Posted by Stephan Jacobs on May 19th, 2026

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.16 and traded as low as $2.56. XTL Biopharmaceuticals shares last traded at $2.6450, with a volume of 54,162 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Get Our Latest Stock Report on XTLB

XTL Biopharmaceuticals Price Performance

The company has a market cap of $5.82 million, a P/E ratio of -4.13 and a beta of 1.64. The company has a fifty day simple moving average of $2.61 and a 200-day simple moving average of $6.16.

About XTL Biopharmaceuticals

(Get Free Report)

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.